European Journal of Cancer
Volume 41, Issue 4 , Pages 516-522 , March 2005

The potential of statins as part of anti-cancer treatment

Received 15 November 2004 ,Accepted 6 December 2004.

References 

  1. Editorial. OTC statins: a bad decision for public health. The Lancet 2004, 363, 1659
  2. Wejde J, Hjertman M, Carlberg M, et al. Dolichol-like lipids with stimulatory effect on DNA synthesis: substrates for protein dolichylation. J Cell Biochem. 1998;71:502–514
  3. Bos JL. Ras oncogenes in human cancer. Cancer Res. 1989;49:4682–4689
  4. Collisson EA, Kleer C, Wu M, et al. Atorvastatin prevents RhoC isoprenylation, invasion, and metastasis in human melanoma cells. Mol Cancer Ther. 2003;2:941–948
  5. Dimitroulakos J, Ye LY, Benzaquen M, et al. Differential sensitivity of various pediatric cancers and squamous cell carcinomas to lovastatin-induced apoptosis: therapeutic implications. Clin Cancer Res. 2001;7:158–167
  6. Feleszko W, Balkowiec EZ, Sieberth E, et al. Lovastatin and tumor necrosis factor-α exhibit potentiated antitumor effects against Ha-ras-transformed murine tumor via inhibition of tumor-induced angiogenesis. Int J Cancer. 1999;81:560–567
  7. Kusama T, Mukai M, Iwasaki T, et al. Inhibition of epidermal growth factor-induced RhoA translocation and invasion of human pancreatic cancer cells by 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors. Cancer Res. 2001;61:4885–4891
  8. Wächterhäuser A, Akoglu B, Stein J. HMG-CoA reductase inhibitor mevastatin enhances the growth inhibitory effect of butyrate in the colorectal carcinoma cell line Caco-2. Carcinogenesis. 2001;22:1061–1067
  9. Rao S, Porter DC, Chen X, et al. Lovastatin-mediated G1 arrest is through inhibition of the proteasome, independent of hydroxymethyl glutaryl-CoA reductase. Proc Natl Acad Sci USA. 1999;96:7797–7802
  10. Kim WS, Kim MM, Choi HJ, et al. Phase II study of high-dose lovastatin in patients with advanced gastric adenocarcinoma. Invest New Drugs. 2001;19:81–83
  11. Okumadu C, Dutta A. p21-dependent inhibition of colon cancer cell growth by mevastatin is independent of inhibition of G1 cyclin-dependent kinases. J Biol Chem. 2003;278:43586–43594
  12. Lee SJ, Ha MJ, Lee J, et al. Inhibition of the 3-hydroxy-3-methylglutaryl-coenzume A reductase pathway induces p53-independent transcriptional regulation of p21 (WAF1/CIP1) in human prostate carcinoma cells. J Biol Chem. 1998;273:10618–10623
  13. Gniadecki R. Depletion of membrane cholesterol causes ligand-independent activation of Fas and apoptosis. Biochem Biophys Res Commun. 2004;320:165–169
  14. Werner M, Sacher J, Hohenegger M. Mutual amplification of apoptosis by statin-induced mitochondrial stress and doxorubicin toxicity in human rhabdomyosarcoma cells. Br J Pharmacol. 2004;143:715–724
  15. Frick M, Dulak J, Cisowski J, et al. Statins differentially regulate vascular endothelial growth factor in endothelial and vascular smooth muscle cells. Atherosclerosis. 2003;170:229–236
  16. Asakage M, Tsuno NH, Kitayama J, et al. 3-Hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor (pravastatin) inhibits endothelial cell proliferation dependent on G1 cell cycle arrest. Anti-Cancer Drugs. 2004;15:625–632
  17. Kusama T, Mukai M, Iwasaki T, et al. 3-Hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors reduce human pancreatic cancer cell invasion and metastasis. Gastroenterology. 2002;122:308–317
  18. Nubel T, Dippold W, Kleinert H, et al. Lovastatin inhibits Rho-regulated expression of E-selectin by TNFalpha and attenuates tumor cell adhesion. FASEB J. 2004;18:140–142
  19. Silva J, Beckedorf A, Bieberich E. Osteoblast-derived oxysterol is a migration-inducing factor for human breast cancer cells. J Biol Chem. 2003;278:25376–25385
  20. Yang B-W, Wang Y-S, Lin S-J. Ras signaling is involved in the expression of Fas-L in glioma. Lab Invest. 2000;80:529–537
  21. Shepherd J, Blauw GJ, Murphy MB, et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. The Lancet. 2002;360:1623–1630
  22. Bjerre LM, LeLorier J. Do statins cause cancer? A meta-analysis of large randomized trials. Am J Med. 2001;110:716–723
  23. Coogan PF, Rosenberg L, Palmer JR, et al. Statin use and the risk of breast and prostate cancer. Epidemiology. 2002;13:262–267
  24. Kaye JA, Meier CR, Walker AM, et al. Statin use, hyperlipidaemia, and the risk of breast cancer. Br J Cancer. 2002;86:1436–1439
  25. Boudreau DM, Gardner JS, Malone KE, et al. The association between 3-hydroxy-3-methylglutaryl coenzyme A inhibitor use and breast carcinoma risk among postmenopausal women: a case-control study. Cancer. 2004;100:2308–2316
  26. Graaf MR, Beiderbeck AB, Egberts ACG, et al. The risk of cancer in users of statins. J Clin Oncol. 2004;22:2388–2394
  27. Poynter JN. HMG-CoA reductase inhibitors and the risk of colorectal cancer. Proc ASCO. 2004;22(14S):1
  28. Blais L, Desgagné A, LeLorier J. 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors and the risk of cancer. Arch Intern Med. 2000;160:2363–2368
  29. Thibault A, Samid D, Tompkins AC, et al. Phase I study of lovastatin, an inhibitor of the mevalonate pathway, in patients with cancer. Clin Cancer Res. 1996;2:483–491
  30. Larner J, Jane J, Klaws E, et al. A phase I-II trial of lovastatin for anaplastic astrocytoma and glioblastoma multiforme. Am J Clin Oncol. 1998;21:579–583
  31. Knox JJ, Siu LL, Chen E, et al. A phase I trial of prolonged administration of lovastatin in patients with recurrent or metastatic squamous cell carcinoma of the head and neck or of the cervix. Eur J Cancer, (this issue)
  32. Chan KKW, Oza AM, Siu LL. The statins as anticancer drugs. Clin Cancer Res. 2003;9:10–19
  33. Kawata S, Yamasaki E, Nagase T, et al. Effect of pravastatin on survival in patients with advanced hepatocellular carcinoma. A randomized controlled trial. Br J Cancer. 2001;84:886–891
  34. Mantha AJ, McFee KE, Niknejad N, et al. Epidermal growth factor receptor-targeted therapy potentiates lovastatin-induced apoptosis in head and neck squamous cell carcinoma cells. J Cancer Res Clin Oncol. 2003;129:631–641
  35. Soma MR, Baetta R, De Renzis MR, et al. In vivo enhanced antitumor activity of carmustine [N,N′-bis (2-chloroethyl)-N-nitrosourea] by simvastatin. Cancer Res. 1995;55:597–602
  36. Wang W, Collie-Duguid E, Cassidy J. Cerivastatin enhances the cytotoxicity of 5-fluorouracil on chemosensitive and resistant colorectal cancer cell lines. FEBS Lett. 2002;531:415–420
  37. Agarwal B, Bhendwal S, Halmos B, et al. Lovastatin augments apoptosis induced by chemotherapeutic agents in colon cancer cells. Clin Cancer Res. 1999;5:2223–2229
  38. Feleszko W, Mlynarczuk I, Balkowiec-Iskra EZ, et al. Lovastatin potentiates antitumor activity and attenuates cardiotoxicity of doxorubicin in three tumor models in mice. Clin Cancer Res. 2000;6:2044–2052
  39. Feleszko W, Mlynarczuk I, Olszewska D, et al. Lovastatin potentiates antitumor activity of doxorubicin in murine melanoma via an apopotosis-dependent mechanism. Int J Cancer. 2002;100:111–118
  40. Muller-Tidow C, Kiehl M, Sindermann JR, et al. Synergistic growth inhibitory effects of interferon-alpha and lovastatin on bcr-abl positive leukemic cells. Int J Oncol. 2003;23:151–158
  41. Miller AC, Kariko K, Myers CE, et al. Increased radioresistance of EJras-transformed human osteosarcoma cells and its modulation by lovastatin, an inhibitor of p21ras isoprenylation. Int J Cancer. 1993;53:302–307
  42. Katz MS, Minsky BD, Saltz LB, et al. Statin use may increase the pathological complete response rate after neoadjuvant chemoradiation for rectal cancer. Proc Am Soc Clin Oncol. 2004;[abstract 3568]

PII: S0959-8049(04)00996-7

doi: 10.1016/j.ejca.2004.12.009

European Journal of Cancer
Volume 41, Issue 4 , Pages 516-522 , March 2005

Article Tools

* Image Usage & Resolution